FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
At the Companys 2017 annual meeting of stockholders held on
June7, 2017, the stockholders voted on the four proposals listed
below. The proposals are described in detail in the Companys
definitive proxy statement for the 2017 annual meeting, filed
with the Securities and Exchange Commission on April24, 2017.The
results of the matters voted upon at the meeting were:
| (a) |
All of the Class III nominees of the Board were elected to hold office until the Companys 2020 annual meeting of stockholders. The nominees were: (i)Thomas F. Kearns Jr: 37,733,019 shares of Common Stock voted for, 2,056,980 withheld, and 12,427,475 broker non-votes; (ii)Kalevi Kurkijrvi, Ph.D.: 38,174,142 shares of Common Stock voted for, 1,615,857 withheld, and 12,427,475 broker non-votes; and (iii)Toshinari Tamura, Ph.D.: 38,163,332 shares of Common Stock voted for, 1,626,667 withheld, and 12,427,475 broker non-votes. |
The term of office of directors Thomas B. Neff, Jeffrey W.
Henderson and James A. Schoeneck continues until the Companys
2018 annual meeting of stockholders. The term of office of
directors Jeffrey L. Edwards, Rory B. Riggs, Roberto Pedro
Rosenkranz, Ph.D., M.B.A., and Jorma Routti, Ph.D. continues
until the Companys 2019 annual meeting of stockholders.
| (b) |
The stockholders approved, on an advisory basis, the compensation of the Companys named executive officers, as disclosed in the 2017 definitive proxy statement:39,123,794 shares of Common Stock voted for, 536,281 against, and 129,924 abstaining. |
| (c) |
The stockholders approved of holding a vote, on an advisory basis, on the compensation of the Companys named executive officers Every Year:35,409,271 shares of Common Stock voted for Every Year, 235,727 voted for Every Two Years, 4,092,531 voted for Every Three Years, and 52,470 abstaining. |
| (d) |
The stockholders ratified the selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its year ending December31, 2017: 52,118,719 shares of Common Stock voted for, 67,829 against, and 30,926 abstaining. |
About FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.
